Top Insider Buys and Sells Disclosed for Friday

Friday’s disclosures in the U.S. stock market featured a number of notable insider trades, and this roundup highlights the most significant buys and sells reported.

Top buys

Enovis Corp. recorded two notable insider purchases last week while its shares hovered near a 52-week low. CEO and Director Damien McDonald bought 13,035 shares on September 4, 2026, for roughly $249,620, paying between $19.10 and $19.16 per share. After that transaction, McDonald directly owns 247,077 shares worth approximately $4.6 million. The timing stands out because the stock now trades at $18.56, close to its 52-week low of $18.52, after sliding 25% over the past week. InvestingPro data indicates the shares look undervalued, with a Fair Value implying 35% upside.

Enovis Corp. also received a vote of confidence from Chief Administrative Officer Oliver Engert, who invested $149,970 in company stock. On September 2, 2026, Engert bought 2,458 shares at a weighted average price of $20.32 per share, with individual trade prices between $20.145 and $20.50. The purchase arrives with shares at $18.56, just above their 52-week low of $18.52, following a sharp 25% decline over the past week. InvestingPro’s analysis sees the stock as undervalued at current levels; the company’s market capitalization stands at $1.12 billion.

Atara Biotherapeutics director Brian N. Cherry acquired 104,166 shares of common stock on September 4, 2026. The transaction was executed at $9.6 per share, for an aggregate value of approximately $999,993. Following the purchase, Cherry directly holds 166,486 Atara shares. The acquisition was made directly from Atara Biotherapeutics through its sales agent, TD Securities (USA) LLC, under a Sales Agreement dated November 1, 2023. The stock currently trades at $9.76, reflecting an 81% surge over the past six months. InvestingPro’s assessment indicates the shares appear overvalued versus Fair Value, with the company’s market capitalization at $95.66 million.

Smith-Midland Corp. attracted insider buying from both its CEO and a director last week. Director Matthew I. Smith bought 2,000 shares in an open-market transaction on September 2, 2026, paying $27.15 per share for a total of $54,300. The purchase is notable because the stock trades near its 52-week low of $24.63 and is down 27% year-to-date. InvestingPro’s Fair Value assessment suggests SMID is undervalued, making the insider purchase potentially more significant. The company holds a GREAT financial health score and has remained profitable over the last twelve months.

Smith Midland Corp. CEO and Director Ashley B. Smith also bought 2,000 shares of common stock on September 1, 2026. The open-market purchase totaled $53,740, with shares acquired at $26.87 apiece. After the transaction, Smith directly owns 180,539 shares of Smith Midland Corp. The purchase comes with shares trading near their 52-week low of $24.63 and down 36% over the past year. According to InvestingPro analysis, SMID appears undervalued at current levels, with the platform’s Fair Value pointing to upside. InvestingPro carries 7 additional exclusive tips for SMID investors.

Top sells

Illumina director and 10% owner Keith A. Meister sold an aggregate of $57,199,200 worth of common stock across several transactions in early September 2026. Sales were executed at prices from $213.20 to $221.55 per share, according to a recent SEC Form 4 filing, with transactions on September 2, 3, and 4, 2026. The shares were sold directly but held for accounts of private investment funds collectively known as the Corvex Funds. Corvex Management LP, the investment adviser for those funds, is controlled by Meister. At the time of the trades, Illumina had posted an 80% return over the previous year and was trading near its 52-week high, per InvestingPro data.

Caris Life Sciences, Inc. President David Baxley Spetzler disposed of $14,834,106 in common stock while acquiring $3,050,000 through option exercises, per a recent SEC filing. The transactions took place September 3 and 4, 2026. On September 3, Spetzler exercised options for 1,000,000 shares at $2.44 per share. At the same time, he sold 393,100 shares at a weighted average price of $24.7604, in multiple trades ranging from $24.3200 to $25.3100. A further 84,900 shares were sold at a weighted average price of $25.3201, with individual prices from $25.3200 to $25.3300. The insider sales come as Caris Life Sciences trades at $25.07, for a market capitalization of $7.16 billion. InvestingPro’s analysis suggests the stock is overvalued relative to its Fair Value estimate, though shares have returned 26% over the past six months.

Okta, Inc. Chief Financial Officer Brett Tighe sold 80,000 shares of Class A Common Stock on September 2, 2026, for total proceeds of $12,877,468. The sales were executed at prices ranging from $158.51 to $167.0867 per share. They were made under a Rule 10b5-1 trading plan adopted by Tighe on April 8, 2026. Of the shares sold, 38,749 were owned directly by Tighe and 41,251 were held indirectly through a trust. The sale comes as Okta trades near its 52-week high of $174.85, following a 90% return over the past year. InvestingPro’s data suggests the stock is overvalued relative to its Fair Value, a factor for those monitoring insider activity.

Krystal Biotech, Inc. President and CEO Krish S. Krishnan sold 25,900 common shares on September 4, 2026, for roughly $8.98 million. The sales were made under a Rule 10b5-1 trading plan adopted on September 4, 2025, which has now terminated. Shares were sold in multiple transactions at prices from $353.98 to $366.91. Among those, 520 shares were sold at a weighted average price of $354.54, or $184,360, with individual trades between $353.98 and $354.97. The sale comes with the stock near its 52-week high of $382.54, following a 139% return over the past year. InvestingPro’s analysis sees the shares as undervalued, with a Fair Value of $383.82, placing it on the list of most undervalued stocks. The company also maintains gross profit margins of 95%, and 18 additional InvestingPro Tips are available for deeper analysis.

Krystal Biotech Inc. President of Research & Development Suma Krishnan also sold 27,000 shares of common stock for approximately $8.98 million. The transactions took place on September 4, 2026, under a Rule 10b5-1 trading plan that has concluded. The sales included 520 shares at a weighted average price of $354.54, for $184,360, and another 26,480 shares at weighted average prices from $355.5719 to $366.556, totaling $8,798,624. The sales occur as KRYS stock trades near its 52-week high of $382.54, following a 139% return over the past year. InvestingPro’s analysis indicates the stock remains undervalued relative to Fair Value, with gross profit margins of 95%. Investors can access 18 additional InvestingPro Tips for more detail on KRYS’s financial health and valuation.

Monitoring insider trading activity can provide useful perspective on how executives and directors view their companies’ prospects. Insider purchases may indicate confidence in future performance, while sales can reflect a range of personal financial planning needs. These transactions should be weighed alongside other fundamental and technical factors when making investment decisions. Tracking such moves can help investors gauge the sentiment of those with the closest knowledge of their companies’ operations and outlook.

This article was produced with the support of AI and reviewed by an editor. Please see our Terms & Conditions for more information.